Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting

Journal of Clinical Oncology

Volumn 21, Issue 16, 2003, Pages 3060-3065

  Taussig, D C ^a   Davies, A J ^a   Cavenagh, J D ^a   Oakervee, H ^a   Syndercombe Court, D ^a   Kelsey, S ^a   Amess, J A L ^a   Rohatiner, A Z S ^a   Lister, T A ^a   Barnett, Michael J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; BONE MARROW APLASIA; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SURGICAL MORTALITY; VIRUS REACTIVATION; ACUTE DISEASE; EVALUATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; MIDDLE AGED; MYELOID LEUKEMIA;

ACUTE DISEASE; ADULT; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING;

EID: 0041411503     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.057     Document Type: Article

References (34)

1. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
2. Rowlings PA, Przepiorka D, Klein JP, et al: IBMTR severity index for grading acute graft-versus-host disease: Retrospective comparison with Gluksberg grade. Br J Haematol 97:855-864, 1997
3. de Witte T, Hermans J, Vossen J, et al: Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:620-630, 2000
4. Litzow MR, Perez WS, Klein JP, et al: Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 119:1115-1124, 2002
5. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukaemia without myeloablative therapy. Blood 89: 4531-4536, 1997
6. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
7. Childs R, Clave E, Contentin N, et al: Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234-3241, 1999
8. Kottaridis PD, Milligan DW, Chopra R, et al: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425, 2000
9. McSweeney PA, Niederwieser D, Shizuru JA, et al: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400, 2001
10. Corradini P, Tarella C, Olivieri A, et al: Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99:75-82, 2002
11. Marks DI, Lush R, Cavenagh J, et al: The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100:3108-3114, 2002
12. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
13. Bearman S, Appelbaum FR, Buckner CD, et al: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568, 1988
14. Glucksberg H, Storb R, Fefer A, et al: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295-304, 1974
15. Shulman HM, Sullivan KM, Weiden PL, et al: Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204-217, 1980
16. Hasskamp J, Syndercombe Court D, Phillips CP, et al: Short tandem repeat analysis to monitor chimerism after bone-marrow transplantation, in Olaisen B, Brinkmann B, Lincoln PJ (eds): Progress in Forensic Genetics 7. Amsterdam, the Netherlands, Elsevier Science, 1998, pp 162-164
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Ratanatharathorn V, Nash RA, Przepiorka D, et al: Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92:2303-2314, 1998
19. Ringden O, Labopin M, Bacigalupo A, et al: Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 20:4655-4664, 2002
20. Couban S, Simpson DR, Barnett MJ, et al: A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100:1525-1531, 2002
21. Sierra J, Perez WS, Rozman C, et al: Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100: 1997-2004, 2002
22. Ferrant A, Labopin M, Frassoni F, et al: Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission-A European Group for Blood and Marrow Transplantation study. Blood 90:2931-2938, 1997
23. Nevill TJ, Fung HC, Shepherd JD, et al: Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92:1910-1917, 1998
24. Martino R, Caballero MD, Perez Simon JA, et al: Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100:2243-2245, 2002
25. Hill GR, Crawford JM, Cooke KR, et al: Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204-3213, 1997
26. Deeg HJ, Spitzer TR, Cottler-Fox M, et al: Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/ cyclosporine prophylaxis. Bone Marrow Transplant 7:193-198, 1991
27. Baurmann H, Nagel S, Binder T, et al: Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood 92:3582-3590, 1998
28. Atkinson K, Horowitz MM, Gale RP, et al: Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459-2464, 1990
29. Sullivan KM, Agura E, Anasetti C, et al: Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250-259, 1991
30. Kolb H-J, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995
31. Feinstein LC, Sandmaier BM, Hegenbart U, et al: Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 120:281-288, 2003
32. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al: Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-Report of the French Society of Bone Marrow Transplantation. J Clin Oncol 18:963-971, 2000
33. Parker JE, Shafi T, Pagliuca A, et al: Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119:144-154, 2002
34. Bacigalupo A: Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 25:803-805, 2000